Tomokazu Kawaoka

Hiroshima University — Japan

Medicine · Health Sciences

40h-index5.2kcitations283works15.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(129), Liver Disease Diagnosis and Treatment(129), Hepatitis C virus research(95), Hepatitis B Virus Studies(56), Liver Disease and Transplantation(40)

Publications282 total

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study
Liver Cancer·2025Open Access
Knowledge Enlightenment About Viral Hepatitis Using a Quiz at an Awareness-Raising Event
Kanzo·2025· 1 citedOpen Access
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis
Liver Cancer·2025Open Access
Evaluation of the Safety and Therapeutic Effect of Multidisciplinary Treatment strategy involving RT after HAIC followed by immunotherapy for Advanced Hepatocellular Carcinoma with Major Vascular Invasion: A Prospective Registry Study (Preprint)
2025Open Access
1488P Patterns of physical activity (PA) measured by wearable devices during atezolizumab plus bevacizumab combination therapy (Atezo+Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the ELIXIR study
Annals of Oncology·2025
Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease
Journal of Pharmaceutical Health Care and Sciences·2025Open Access
Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients
Journal of Gastroenterology·2025· 4 citedOpen Access
Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma
Journal of Gastroenterology·2025· 2 citedOpen Access
THU-337 Is the POISE really valid as a surrogate endpoint for patients with PBC treated with UDCA and PPAR agonist? – a retrospective validation study from the real-world data in Japan
Journal of Hepatology·2025
Spontaneous Intratumoral Hemorrhage in Hepatic Hemangioma with Acute Abdominal Pain: A Case Report
Kanzo·2025Open Access
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma
Anticancer Research·2025· 2 citedOpen Access
Intracellular enhancement technique for gadoxetic acid-enhanced hepatobiliary-phase magnetic resonance imaging: evaluation of hepatic function
Abdominal Radiology·2025Open Access
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE trial final results.
Journal of Clinical Oncology·2025· 3 cited
Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B
Journal of Gastroenterology·2025· 2 citedOpen Access
The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma
Internal Medicine·2025Open Access
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet·2025· 153 citedOpen Access
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Journal of Gastroenterology·2024· 9 citedOpen Access
First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Oncology·2024· 7 citedOpen Access
Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single‐institution study
Hepatology Research·2024· 2 citedOpen Access
A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine
Clinical Journal of Gastroenterology·2024Open Access
page 1 of 15Next →

Frequent Co-authors

Kazuaki Chayama(45), Hiroshi Aikata(42), Michio Imamura(38), Masataka Tsuge(31), Akira Hiramatsu(31), Takashi Nakahara(27), Shoichi Takahashi(24), Eisuke Murakami(23), Yoshiiku Kawakami(22), Kei Morio(20), Daiki Miki(16), C. Nelson Hayes(15), Shintaro Takaki(15), Shinsuke Uchikawa(15), Hatsue Fujino(14), Yuko Nagaoki(13), Hidenori Ochi(13), Hideyuki Hyogo(13), Atsushi Ono(13), Nobuhiko Hiraga(10)